Form 4: Viridian Therapeutics Director Sarah Gheuens Acquires Stock Options
SEC Form 4 Filing
Director Sarah Gheuens acquired stock options for 21,000 shares of Viridian Therapeutics, Inc.
Summary
- Sarah Gheuens, a director of Viridian Therapeutics, Inc., filed a Form 4 indicating a transaction involving derivative securities.
- On June 26, 2024, Gheuens acquired stock options for 21,000 shares of common stock at an exercise price of $12.31 per share.
- The options vest upon the earlier of June 26, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service on the Board.
- Following the reported transaction, Gheuens directly owns derivative securities for 21,000 shares.
- A Power of Attorney was executed on June 26, 2024, granting Thomas Beetham, Seth Harmon, and Jennifer Tousignant the authority to execute Forms 3, 4, and 5 on behalf of Sarah Gheuens.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which is neither overwhelmingly positive nor negative.
Positives
- Acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the stock options is contingent upon continued service on the Board until at least June 26, 2025, or the company's 2025 annual meeting.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Viridian Therapeutics.
- Comparable companies such as Alnylam Pharmaceuticals, BioMarin Pharmaceutical, and Sarepta Therapeutics also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders.
Stakeholder Impact
- The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of stock option acquisition and Power of Attorney execution. |
| 06/26/2024 | Earliest transaction date. |
| 06/26/2025 | First possible vesting date for the stock options. |
| 06/26/2034 | Expiration date of the stock options. |
| 06/28/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.